SecBot SecBot

QNTM

Quantum Biopharma Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. A6· CIK 0001771885 Biotech & Drug Discovery
$2.21 −0.03 (−1.34%)
Oct 26 4:00 PM ET · prev $2.24
Market cap
$19.2M
Nano cap
Median target
🔒 Subscribers only
1 year
−83.5%
from $13.43 · Oct 27
30 days
−44.2%
from $3.96
52-week range
$2.10–13.43
−84% from high · low Mar 11
Avg volume 20D
145.2K
Oct 6 spike 618.8K
Short interest
361.1K
≈4.5% of shares · +48.9%
Days to cover
1.6
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 15 reports · 90 days
Balance 0 bearish · 3 bullish · 12 neutral oldest → newest, height = score
Avg score ·High conf. 9/15
Strongest NEUTRAL Quantum BioPharma announced that the U.S. District Court for the Southern District of New York consolidated…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 6 added (0 new), 1 trimmed or exited.

  • Short sellersBUILDING

    Short interest +48.9% to 361.1K shares. 1.6 days to cover, ≈4.5% of shares.

  • TrendDOWNTREND

    31% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCADD48,355$175.0K
UBS Group AGDOUBLED33,405$120.9K
Steward Partners Investment Advisory, LLCDOUBLED27,881$100.9K
JONES FINANCIAL COMPANIES LLLPADD1,209$4.6K
ROYAL BANK OF CANADADOUBLED446$2.0K
WELLS FARGO & COMPANY/MNDOUBLED250$907.00
TD Waterhouse Canada Inc.TRIM6$20.00
JANE STREET GROUP, LLCDOUBLED31,501$152.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Earnings setup

Estimates
−$0.59
EPS estimate, this quarter
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.59-$0.59–-$0.59—$0.00
Next Q-$0.70-$0.70–-$0.70—$0.00
Current FY-$2.58-$2.58–-$2.58—$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 6, 2026
Contract
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study…
Sep 1, 2026
Delisting
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR…
Aug 21, 2026
Activist
Quantum Biopharma Provides Corporate Update
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR…
Aug 14, 2026
Earnings
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported…
Jul 30, 2026
Activist
Quantum BioPharma Announces Closing of Debt Settlement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR…

Short side

FINRA· Sep 30, 2026
361,097
shares short
+48.9%
vs prior settlement
1.6
days to cover
≈4.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
Quantum BioPharma announced that the U.S. District Court for the Southern District of New York consolidated its direct…
6-K — Impact 4/10
Oct 6, 2026 SEC
Quantum BioPharma announced it has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research…
6-K — Impact 4/10
Oct 6, 2026 Press
Quantum BioPharma announced a Study Start-Up Agreement with Thermo Fisher's PPD clinical research business to initiate…
Impact 4/10
Oct 6, 2026 Contract
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Strategic collaboration with leading global contract research organization to implement randomized,
Oct 5, 2026 SEC
AdvisorShares Trust filed an amended Schedule 13G disclosing a 4.95% passive stake in Quantum Biopharma Ltd. as of…
SC 13G/A — Impact 3/10
Sep 1, 2026 Press
Quantum BioPharma (QNTM) announced it has applied for a voluntary delisting from the Canadian Securities Exchange…
Impact 3/10
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — ADD
48,355 shares ($175.0K)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
33,405 shares ($120.9K)

SecBot reports

20 filings · 10 press releases · 7 bullish · 1 bearish · 12 neutral
All QNTM filing & press-release reports (30)